Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva swoops on Auspex with $3.2bn acquisition

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals in an all cash deal valuing the CNS-focused firm at $3.2bn. Teva executives underlined that the deal did not preclude other, bigger, deals that it is still hoping to make.

Advertisement

Related Content

Teva Set For Immediate US Launch Of Austedo In Tardive Dyskinesia

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel